2025 Update on resistant hypertension in CKD: where do we stand and where do we go?
Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii10-ii16
DOI: 10.1093/ckj/sfaf285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 26.09.2025. Verfasst von Roland E Schmieder. Beteiligte Einrichtung: Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen/Nürnberg, Erlangen, Germany. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Resistant hypertension is highly prevalent among individuals with chronic kidney disease (CKD) and is closely associated with accelerated decline of renal function and increased cardiovascular morbidity and mortality. Recent clinical guidelines have established clearer blood pressure (BP) targets for this population, generally recommending office BP values below 140/90 mmHg, with a more stringent target of <130/80 mmHg for patients with albuminuria, diabetes, high cardiovascular risk, or transplant. Conversely, systolic pressure <120 mmHg is not advised due to concerns regarding renal hypoperfusion and associated adverse cardiovascular outcomes. Initial treatment involves an optimized triple therapy regimen with a renin–angiotensin system blocker, a calcium channel blocker, and a diuretic, with the addition of beta-blockers in patients with cardiac comorbidities. Patients with poorly controlled BP require a fourth agent. Spironolactone remains a preferred option when the estimated glomerular filtration rate is ≥30 ml/min/1.73 m², but long-term adherence is poor. Chlorthalidone is suitable in more advanced CKD, particularly combined with loop diuretics. Centrally sympatholytic agents represent a valuable alternative. Sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide 1 receptor agonists have demonstrated both antihypertensive effects and clear renal and cardiovascular benefits. Dual endothelin receptor antagonist may offer an additional option in patients with resistant hypertension. Renal denervation represents another promising approach. In selected cases of atherosclerotic renovascular disease with high-grade stenosis and clinical risk features, revascularization may provide benefit. Collectively, these developments support a more individualized and evidence-based approach to managing resistant hypertension in CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen/Nürnberg, Erlangen, Germany.
Zitieren
APA
Schmieder, R. E. (2025). 2025 Update on resistant hypertension in CKD: where do we stand and where do we go?. Clinical Kidney Journal, 18(Supplement_2), ii10-ii16. https://doi.org/10.1093/ckj/sfaf285
Vancouver
Schmieder RE. 2025 Update on resistant hypertension in CKD: where do we stand and where do we go?. Clinical Kidney Journal. 2025;18(Supplement_2):ii10-ii16. doi:10.1093/ckj/sfaf285
BibTeX
@article{Schmieder2025,
author = {Schmieder, Roland E},
title = {2025 Update on resistant hypertension in CKD: where do we stand and where do we go?},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {Supplement_2},
pages = {ii10--ii16},
doi = {10.1093/ckj/sfaf285}
}
EUVIMED